HUM vs. ELV, CI, CNC, MOH, UNH, OSCR, ALHC, TRUP, CLOV, and NEUE
Should you be buying Humana stock or one of its competitors? The main competitors of Humana include Elevance Health (ELV), The Cigna Group (CI), Centene (CNC), Molina Healthcare (MOH), UnitedHealth Group (UNH), Oscar Health (OSCR), Alignment Healthcare (ALHC), Trupanion (TRUP), Clover Health Investments (CLOV), and NeueHealth (NEUE). These companies are all part of the "hospital & medical service plans" industry.
Humana (NYSE:HUM) and Elevance Health (NYSE:ELV) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.
Humana presently has a consensus price target of $402.60, indicating a potential upside of 2.54%. Elevance Health has a consensus price target of $604.29, indicating a potential upside of 14.55%. Given Elevance Health's stronger consensus rating and higher probable upside, analysts plainly believe Elevance Health is more favorable than Humana.
Humana has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Elevance Health has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.
Elevance Health has higher revenue and earnings than Humana. Elevance Health is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.
Humana pays an annual dividend of $3.54 per share and has a dividend yield of 0.9%. Elevance Health pays an annual dividend of $6.52 per share and has a dividend yield of 1.2%. Humana pays out 22.0% of its earnings in the form of a dividend. Elevance Health pays out 24.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Humana received 40 more outperform votes than Elevance Health when rated by MarketBeat users. However, 67.01% of users gave Elevance Health an outperform vote while only 63.90% of users gave Humana an outperform vote.
Elevance Health has a net margin of 3.89% compared to Humana's net margin of 1.82%. Elevance Health's return on equity of 20.64% beat Humana's return on equity.
In the previous week, Humana and Humana both had 39 articles in the media. Elevance Health's average media sentiment score of 0.34 beat Humana's score of 0.24 indicating that Elevance Health is being referred to more favorably in the news media.
92.4% of Humana shares are owned by institutional investors. Comparatively, 89.2% of Elevance Health shares are owned by institutional investors. 0.3% of Humana shares are owned by insiders. Comparatively, 0.4% of Elevance Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Elevance Health beats Humana on 16 of the 20 factors compared between the two stocks.
Get Humana News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HUM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
